SEC Comment Letter for Tonix Pharmaceuticals Holding Corp. (TNXP) (CIK 0001430306) (TNXP) — Oct 10, 2017
Tonix Pharmaceuticals Holding Corp. (TNXP) (CIK 0001430306)
Date: Oct. 10, 2017 · CIK: 0001430306 · Accession: 0000000000-17-035776
AI Filing Summary & Sentiment
Reasoning
Letter
October 10, 2017 Seth Lederman Chief Executive Officer Tonix Pharmaceuticals Holding Corp. 509 Madison Avenue, Suite 306 New York, New York 10022 Tonix Pharmaceuticals Holding Corp. Registration Statement on Form S-1 Filed September 29, 2017 File No. 333-220749Re: Dear Dr. Lederman: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jeffrey Gabor at 202-551-2544 with any questions. Division of Corporation Finance Office of Healthcare & Insurance cc: James Turner
Show Raw Text
October 10, 2017 Seth Lederman Chief Executive Officer Tonix Pharmaceuticals Holding Corp. 509 Madison Avenue, Suite 306 New York, New York 10022 Tonix Pharmaceuticals Holding Corp. Registration Statement on Form S-1 Filed September 29, 2017 File No. 333-220749Re: Dear Dr. Lederman: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jeffrey Gabor at 202-551-2544 with any questions. Division of Corporation Finance Office of Healthcare & Insurance cc: James Turner